

File No- Letter No.: - BMSIC/40030/175-2024/ 7950

Date: - 14/10/2025

Order

M/s Centurion Laboratories Pvt. Ltd. having its Head Office at P-2, Bio-tech Park, Manjusar, Savli Dist. Vadodara, Gujarat-391775 has participated in **Tender No- BMSIC/DRUGS/22-07**.

The firm, M/s Centurion Laboratories Pvt. Ltd., was declared L1 for the drugs namely **Lopinavir (A) + Ritonavir (B)- Tablet 200 mg (A) + 50 mg (B), Tenofovir+ Lamivudine Tablet - 300 mg+300 mg, Efavirenz Tablet-200 mg** and was declared L2 & L3 for the drugs namely **Lopinavir (A) + Ritonavir (B) Tablet- 100 mg (A) + 25 mg (B), Zidovudine 60 mg + Lamivudine 30 mg + Nevirapine 50 mg Tablet & Lamivudine + Zidovudine Tablet -30 mg + 60 mg** and gave their consent to accept L1 rate and agreed to supply on L1 rate.

The detail of LoI and agreement of the above-mentioned drugs are as follows: -

| S.No | Tender No.        | Name of the Drugs                                             | LoI No. & Dated       | Agreement Dated |
|------|-------------------|---------------------------------------------------------------|-----------------------|-----------------|
| 1    | BMSIC/DRUGS/22-07 | Efavirenz Tablet-200 mg                                       | 3878 dated 07.09.2022 | 19.10.2022      |
| 2    |                   | Lamivudine + Zidovudine Tablet -30 mg + 60 mg                 |                       |                 |
| 3    |                   | Lopinavir (A) + Ritonavir (B) Tablet-100 mg (A) + 25 mg (B)   |                       |                 |
| 4    |                   | Lopinavir (A) + Ritonavir (B)- Tablet 200 mg (A) + 50 mg (B)  |                       |                 |
| 5    |                   | Tenofovir+ Lamivudine Tablet -300 mg+300 mg                   |                       |                 |
| 6    |                   | Zidovudine 60 mg + Lamivudine 30 mg + Nevirapine 50 mg Tablet |                       |                 |

Subsequently, the firm M/s Centurion Laboratories Pvt. Ltd. was issued Purchase Order for above-mentioned 06 Drugs. The detailed summary of non-supply is mentioned below: -

| No. of PO | No. of Drugs | Item Name                                     | PO. No & Dated           | Schedule Date | PO Qty | Received | Delay days as on 10.10.2025 (in addition to schedule date) | 1st Show Cause Issued date | 2nd Show Cause Issued Date | Status     |
|-----------|--------------|-----------------------------------------------|--------------------------|---------------|--------|----------|------------------------------------------------------------|----------------------------|----------------------------|------------|
| 1         | 1            | Efavirenz Tablet-200 mg                       | 10282401015 & 30.04.2024 | 29-Jun-24     | 600    | 0        | 465                                                        | 09.07.2024                 | 23.07.2024                 | Non-Supply |
| 2         |              |                                               | 10282401730 & 22.07.2024 | 20-Sep-24     | 1400   | 0        | 382                                                        | 25.09.2024                 | 07.10.2024                 | Non-Supply |
| 3         |              |                                               | 10282402338 & 19.10.2024 | 18-Dec-24     | 250    | 0        | 293                                                        | 19.12.2024                 | 07.01.2025                 | Non-Supply |
| 4         | 2            | Lamivudine + Zidovudine Tablet -30 mg + 60 mg | 3910 & 08.08.2023        | 07-Oct-23     | 195    | 0        | 731                                                        | 11.10.2023                 | 31.10.2023                 | Non-Supply |
| 5         |              |                                               | 10282401021 & 30.04.2024 | 29-Jun-24     | 165    | 0        | 465                                                        | 09.07.2024                 | 23.07.2024                 | Non-Supply |
| 6         |              |                                               | 10282401736 & 22.07.2024 | 20-Sep-24     | 450    | 0        | 382                                                        | 25.09.2024                 | 07.10.2024                 | Non-Supply |
| 7         |              |                                               | 10282402342 & 19.10.2024 | 18-Dec-24     | 135    | 0        | 293                                                        | 19.12.2024                 | 07.01.2025                 | Non-Supply |




|    |   |                                                               |                          |           |      |   |     |            |            |            |
|----|---|---------------------------------------------------------------|--------------------------|-----------|------|---|-----|------------|------------|------------|
| 8  | 3 | Lopinavir (A) + Ritonavir (B) Tablet-100 mg (A) + 25 mg (B)   | 10282400266 & 20.02.2024 | 20-Apr-24 | 300  | 0 | 535 | 02.05.2024 | 24.05.2024 | Non-Supply |
| 9  |   |                                                               | 10282401460 & 20.07.2024 | 18-Sep-24 | 930  | 0 | 384 | 25.09.2024 | 07.10.2024 | Non-Supply |
| 10 |   |                                                               | 10282402270 & 19.10.2024 | 18-Dec-24 | 150  | 0 | 293 | 19.12.2024 | 07.01.2025 | Non-Supply |
| 11 | 4 | Lopinavir (A) + Ritonavir (B)- Tablet 200 mg (A) + 50 mg (B)  | 10282401834 & 23.07.2024 | 21-Sep-24 | 2170 | 0 | 381 | 25.09.2024 | 07.10.2024 | Non-Supply |
| 12 |   |                                                               | 10282402345 & 19.10.2024 | 18-Dec-24 | 280  | 0 | 293 | 19.12.2024 | 07.01.2025 | Non-Supply |
| 13 | 5 | Tenofovir+ Lamivudine Tablet -300 mg+300 mg                   | 10282401836 & 23.07.2024 | 21-Sep-24 | 2170 | 0 | 381 | 25.09.2024 | 07.10.2024 | Non-Supply |
| 14 |   |                                                               | 10282402356 & 19.10.2024 | 18-Dec-24 | 140  | 0 | 293 | 19.12.2024 | 07.01.2025 | Non-Supply |
| 15 | 6 | Zidovudine 60 mg + Lamivudine 30 mg + Nevirapine 50 mg Tablet | 3910 & 08.08.2023        | 07-Oct-23 | 300  | 0 | 731 | 11.10.2023 | 31.10.2023 | Non-Supply |
| 16 |   |                                                               | 10282400267 & 20.02.2024 | 20-Apr-24 | 150  | 0 | 535 | 02.05.2024 | 24.05.2024 | Non-Supply |
| 17 |   |                                                               | 10282400908 & 29.04.2024 | 28-Jun-24 | 360  | 0 | 466 | 09.07.2024 | 23.07.2024 | Non-Supply |
| 18 |   |                                                               | 10282401513 & 20.07.2024 | 18-Sep-24 | 360  | 0 | 384 | 25.09.2024 | 07.10.2024 | Non-Supply |
| 19 |   |                                                               | 10282402331 & 19.10.2024 | 18-Dec-24 | 750  | 0 | 293 | 19.12.2024 | 07.01.2025 | Non-Supply |

Despite of several show cause notices, the firm **M/s Centurion Laboratories Pvt. Ltd.** has not started supplying the drugs against all the issued above mentioned Purchase Order as on date. Hence, the firm was found to be habitual defaulter as per Clause 27 (c) (i) of SBD.

The firm was issued two show cause notices. In spite of that the firm was unable to supply. Lastly, BMSICL issued a mail on dated 22.09.2025 for the supply of small batch size drug with sticker of BMSICL logo and stamp of Bihar Govt. Supply, Not for sale. The firm replied in its mail dated 23.09.2025 that *“due to batch size constraint, we cannot manufacture this much small quantity”*. The reply of the firm was found to be unsatisfactory and this is the violation of clause 27 A and 27 C of the standard bid document.

The firm also replied in its mail dated 19.12.2024 that *“due to very less quantity, we cannot manufacture these items and cannot supply this much of small quantity to different destination, as our standard batch size for tablet is 1,00,000 to 1,50,000 tablets. It is very difficult to bear production, transportation and testing charges for too small quantity”*. The reply of the firm was found to be unsatisfactory and this is the violation of clause 27 A and 27 C of the standard bid document.

This pattern of behaviour places the firm under the purview of a habitual defaulter. This is the violation of Clause 27(C) of the Standard Bidding Document.

Annexure-I of the standard bid document states that *“Tendered quantity is just a tentative quantity and shouldn't be treated as final. It may increase or decrease, as per need of the State. Keeping this in mind, the supplier isn't allowed to seek termination of the Rate Contract after finishing supply of tendered quantity”*.

Clause 27 A of the Standard Bid Document stipulates that: -

**“If the Tenderer fails to execute the agreement / to deposit performance security / to perform the obligations under the tender conditions / commits default in the performance**



*of the contract/agreement, such Tenderers will be blacklisted for a period of 2 years by BMSICL from the date of intimation besides forfeiture of EMD/Performance Guarantee. The Tenderers who have withdrawn after participating in the tender either fully or partially, the entire firm/company will be blacklisted for a period of 2 years from the date of intimation by BMSICL apart from forfeiture of the Security Deposit/EMD”.*

Clause 27 C of the Standard Bid Document stipulates that: - **“BLACKLISTING FOR NON-SUPPLY/ PART SUPPLY/DELAYED SUPPLY/NON-FULFILLMENT OF CONTRACT OBLIGATION: -**

*Notwithstanding various actions and penalties for non-supply and/or delayed supply of the drugs and medicines as stipulated in the terms and conditions of the tender, the BMSICL, shall take action against the supplier as follows:*


*(i) Incase, the supplier is found to be habitual defaulter of delayed supply or not supplying the full quantity in time, the balance amount of performance security of such company shall be forfeited. No further supply order shall be given to them and company shall be barred from participating in any tender floated by BMSICL, further other punitive action such as blacklisting of the firm for a minimum period of 2 years from the date of intimation for blacklisting/debarring.*

*(ii) Purchase orders, if any, already issued before taking any blacklisting action or orders given in past will not be affected in view of action taken as per above guidelines but all strict quality checks shall be observed for each supply of products.*

*The blacklisting of particular product or company/firm will be done without prejudice to other penalties which may be imposed as per the conditions of Tender documents and also to other actions which may be initiated under Drugs and Cosmetics Act, 1940 or any other law of Land. BMSICL will display names of such blacklisted product(S) and company/firm on its website for general notice.”*

**All the above-mentioned drugs are lifesaving drug which are useful for Patient of HIV etc.** This activity of the firm of non-supply of such important medicines is adversely affecting the objectives of BMSICL i.e. Free Drugs supply to every patient at all Government Health Facilities in the State of Bihar within the stipulated time period.

Thus, in light of the provisions contained in the tender document, **M/s Centurion Laboratories Pvt. Ltd.** having its Head Office at P-2, Bio-tech Park, Manjusar, Savli Dist. Vadodara, Gujarat-391775 is hereby blacklisted for a period of three (3) years from the date of issue of this order apart from forfeiture of security deposit and EMD.

  
(Managing Director)

Memo No. BMSIC/40030/175-2024/ 7950

Date: -14/10/2025

Copy to: The Managing Director M/s Centurion Laboratories Pvt. Ltd. For information and needful action.

  
(Managing Director)




**Memo No.**

**Date: -**

**Copy to:**

1. The Secretary, Department of Health, Govt. of Bihar for kind Information please.
2. Executive Director, State Health Society, Bihar for kind Information please.
3. The CGM (Supply Chain), General Manager (Logistics), General Manager (Finance), BMSICL for information and necessary action. GM (Logistics) is requested to ensure publication of this order on the official website of BMSICL and Notice Board as well.
4. MD, All Medical Corporations and Procurement Agencies all over India for Information and necessary action please.
5. CEO, Government e-Marketplace for information and necessary action please.
6. All Civil Surgeons, Bihar and Superintendents of all Govt. medical colleges and hospitals of Bihar for information and necessary action.
7. All the concerned manufacturer having rate contract with BMSICL for information.

  
(Managing Director)

